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Abstract 
 Liver cancer is the 6th most common cancer worldwide. Hepatocellular carcinoma (HCC) is the 
major form of liver cancer with no effective therapy. Genetic modification with T cell receptors (TCR) 
specific for HCC-associated tumor antigens, such as α-fetoprotein (AFP), can potentially redirect human 
T cells to specifically recognize and kill HCC tumor cells to achieve antitumor effect. In this study, using 
lentivector and AFP peptide immunization, we identified a population of HLA-A2 transgenic mouse 
CD8-T cells that were able to recognize the AFP158 epitope on human HCC tumor cells. Adoptive transfer 
of the AFP158-specific CD8-T cells derived from the immunized HLA-A2 mice eradicated HepG2 tumor 
xenografts as large as 2cm in diameters in the immunocompromised NSG mice. We then established 39 T 
cell hybridoma clones from the AFP158-specific mouse CD8-T cells. Next, we identified three unique sets 
of paired TCRα and β chains from 5 hybridoma clones. Expression of the murine TCR genes redirected 
primary human CD8 and CD4 T cells to bind HLA-A2/AFP158 Tetramer. The TCR gene-modified human 
CD8 and CD4 T cells (TCR-T) could specifically recognize HLA-A2+ AFP+ HepG2 tumor cells and 
produced cytokines of IFNγ and IL-2. Importantly, both CD8 and CD4 TCR-T cells could specifically kill 
HLA-A2+ AFP+ HepG2 tumor cells in vitro. Adoptive transfer of the AFP-specific human TCR-T cells 
could eradicate HepG2 tumors in NSG mice. Conclusion: We have identified novel AFP-specific murine 
TCR genes that can redirect human T cells to specifically recognize and kill HCC tumor cells and these 
AFP158-specific TCRs have a great potential to engineer patient’s autologous T cells to treat HCC tumors.  
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Introduction 
Approximately 854,000 new cases of liver cancer, 85-90% of which are hepatocellular carcinoma 
(HCC), are diagnosed each year, making it the 6
th
 most common cancer worldwide (1). According to 
American Cancer Society, the incidence rate of liver cancer increases the fastest among all cancers and 
the number of liver cancer has doubled over last decade in the United States likely due to obesity/diabetes 
(2, 3). Liver cancer is also the 2
nd
 leading cause of cancer death in adult man because of lack of therapies 
(4-6). The dismal prognosis urgently demands new therapeutic approaches. Activation of host immune 
system is able to generate significant antitumor effects (7, 8). For example, using checkpoint blockade 
antibodies to unleash patient’s immune responses generates remarkable therapeutic effect in a variety of 
cancers (9) including HCC (10). While this is promising, the antitumor efficacy of PD-1 blockade 
depends on the pre-existence of tumor-specific infiltrating T cells that are not always available (11). 
Additionally, the unleashing of non-specific immune responses by checkpoint blockade may cause 
autoimmune destruction. On the other hand, immunotherapy targeting tumor-specific or tumor-associated 
antigens is, in theory, less likely cause autoimmune diseases.  
The human α-fetoprotein (AFP) is re-expressed in approximately 70-80% of HCC tumor (12, 13), 
which serves as a biomarker for diagnosis and potential target for immunotherapy. Butterfield et al 
originally identified four HLA-A2 restricted AFP epitopes and developed peptide- and vector-based 
vaccines to enhance AFP-specific immune responses (14, 15). Even though modest AFP epitope-specific 
CD8 responses were detected in HCC patients, no antitumor effect was observed (16). A more effective 
and specific approach of tumor immunotherapy is adoptive transfer of tumor-specific autologous T cells 
(17, 18). Unfortunately, most tumor-specific T cells are low affinity or cannot be expanded from cancer 
patients. One way to obtain high affinity tumor antigen-specific T cells is to genetically modify patient’s 
T cells with tumor-specific T cell receptor (TCR) (19-21). Identification of tumor antigen-specific TCRs 
is the first critical step of T cell engineering and adoptive cell therapy. Recently, Sun et al cloned a AFP158 
epitope-specific TCR from human T cells (22). Not surprisingly, this AFP158-specific TCR has little 
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antitumor effect because of its low affinity. In a meeting abstract, Gerry et al reported that mutations in 
the complementarity-determining region (CDR) of an original AFP158-specific human TCR (23) could 
increase its affinity (Gerry et al, Journal of ImmunoTherapy of Cancer, 2013 1(Suppl 1): P10) and 
showed that human T cells transduced with the affinity-enhanced TCR could better recognize HCC tumor 
cells. The antitumor efficacy of this AFP-specific TCR-T is being tested by clinical trial that has just been 
approved in May of 2017. However, recent reports of severe on-target and off-target toxicity of TCR-T 
(24, 25) suggest that more TCRs are needed in order to select the optimal TCRs that can render human T 
cells the tumor killing activity without toxicity. Furthermore, the frequent immune escape by tumor cells 
indicates that targets multiple epitopes or even multiple antigens is needed in order to achieve long-term 
antitumor effect. Thus, there is a strong demand for more effective and safe AFP-specific TCRs for HCC 
immunotherapy.   
In this study, we developed a novel and effective strategy to identify TCRs specific for HLA-A2 
presented AFP158 epitope. We first found that an immunization approach of lentivector (lv)-prime and 
peptide-boost could elicit high level of CD8 responses in HLA-A2 mice. The large number of AFP158-
specific CD8-T cells without re-stimulation should keep their TCR diversity and enabled us to conduct in 
vitro and in vivo studies to determine their antitumor effects prior to TCR identification. We next found 
that the AFP158-specifc CD8-T cells derived from HLA-A2 mice could recognize and kill human HCC 
tumor cells in vitro and that adoptive transfer of them could eradicate large human HepG2 tumors (2cm in 
diameters) in NSG mice. We then identified three pairs of TCR α and β chain genes from the mouse CD8-
T cells of strong antitumor effects. Transduction of primary human T cells with the TCR genes redirected 
them to effectively and specifically recognize and kill HepG2 tumor cells in vitro. Adoptive transfer of 
the human TCR-T cells eradicated HepG2 tumor in NSG mice. In conclusion, we have identified AFP158-
specific TCRs with a great potential to modify and redirect patient’s autologous T cells for HCC 
treatment.    
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Materials and Methods 
Mice: HLA-A2 transgenic AAD mice (female 7-8weeks old) were from Jackson Laboratory. The AAD 
mice express a chimeric MHCI of HLA-A2 α1-α2 domain (binding peptide) and H-2
d
 α3 domain (binding 
mouse CD8 to help immune priming) (26). Immunocompromised NSG mice (female 7-10weeks old) 
were also from Jackson Laboratory. Animal protocols were approved by the IACUC Committee of 
Augusta University. 
Cell lines: HEK293T and HepG2 cells were from ATCC. Huh7 (HLA-A11) was a gift of Dr. Ande of 
Georgia Cancer Center, and the AFP- HepG2 cell was provided by Dr. Jingxiong She of Augusta 
University. The expression of AFP and HLA of HCC cell lines was verified by western blot and 
immunological staining. The cells were cultured no more than 6-8 passages before using to make sure 
their authenticity. Cell lines were checked for mycoplasma by PCR test (Fisher Scientific). 
Tumor inoculation: Five millions of HepG2 cells were inoculated into the flank of NSG mice. Tumor 
growth was monitored by measuring the length, width, and height. The tumor volume was calculated as 
1/2(length×widthxheight). 
Recombinant lv and immunization: The AFP and influenza virus PR8 M1 genes were cloned into lv to 
generate AFP-lv and Flu-M-lv. Lvs were prepared and tittered as described (27).  Mice were 
subcutaneously immunized with AFP-lv and Flu-M-lv (28) and then boosted 12-15 days later by AFP158 
(FMNKFIYEI) or M158 (GILGFVFTL) peptide with PolyI:C and anti-CD40 antibody as described (29).  
Intracellular staining and ELISA assay: Peripheral blood cells or splenoctes were stimulated with 
AFP158 or M158 peptides in the presence of GolgiStop (Biolegend) for 4hrs and intracellularly stained for 
IFNγ or IL-2 as described (30). ELISA of IFNγ and IL-2 was conducted as instructed (Biolegend).  
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Tetramer staining: Splenocytes were stained with indicated surface markers, Tet158 Tetramers (NIH 
Tetramer Core Facility), and anti-Vβ antibody panel (BD Biosciences). Tetramer staining was conducted 
before anti-Vβ staining to avoid interference.  
T cell hybridomas: T cell hybridomas were created by fusing the sorted mouse CD8+Tet158+ cells with 
BW-Lyt2.4 cells that were lack of TCR α and β chains and selected in HAT medium as described (31). 
Single clones were obtained by serial dilution. 
Identification of paired TCRα and β chains: 5-RACE technique (32) was conducted to amplify the 
TCRα and β genes. Briefly, total RNA was isolated from hybridoma clones. cDNA was made with oligo 
dT primer and PolyC was then added to the 5’ end of cDNA by terminal transferase. PCR was conducted 
using the 5’ pGI primer (CACCGGGIIGGGIIGGGIIGG) and 3’ primers corresponding to the constant 
(C) region of α (GGCATCACAGGGAACG) or β chain (CCAGAAGGTAGCAGAGACCC). Based on 
the obtained sequence of the TCR α and β variable (V) regions, specific primer corresponding to the V 
region of α (ATGAAATCCTTTAGTATTTCCC) or β (ATGGGCTCCAGGCTCTTTCTG) chains were 
used with another internal primer of α C-region (GCACATTGATTTGGGAGTC) or β C-region: 
GGGTAGCCTTTTGTTTGTTTG) to amplify the V region. Nucleotide sequences of the TCR α and β 
chains were obtained.  
TCR genes and recombinant lv: TCRα and β genes were designed from the above identified V-D-J 
region. The C-region of TCRα chain and the C2-region of TCRβ chain were used to create the full length 
TCRs. A P2A sequence (33) is inserted between α and β chains. The entire TCR genes were codon-
optimized, synthesized, and cloned into lv. 
Transduction of human T cells: Human T cells were isolated from buffy coat by negative selection and 
activated by the CD3/CD28 Tetrameric antibody complex (Stemcell Technologies) for 2days before they 
were transduced with lv. The CD3/CD28 antibody complex was rinsed away 2days after stimulation. 
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MTT assay: To measure the live HepG2 cells after overnight co-culture with mouse splenocytes, MTT 
assay was performed as we previously described (34).  
LDH assay and prodidium iodide (PI) staining: The cytotoxicity of TCR-T was determined by 
measuring the LDH activity in the co-culture media as instructed by manufacturer (Promega). And the 
dead HepG2 cells were stained with PI according to manufacturer (BD Biosciences). 
Adoptive cell transfer: Mouse splenocytes, sorted specific T cell populations, or human TCR-T cells of 
indicated numbers were transferred into NSG mice bearing human HepG2 tumors. Cells in the mice were 
monitored by immunological staining.    
Statistical analysis: Statistical analyses were performed using T-test or ANOVA (GraphPad Inc). 
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Results 
1. Immunization of HLA-A2 transgenic mice with lv-prime and peptide-boost elicits high level of 
AFP158-specific CD8-T cells that recognize and kill human HepG2 cells. To induce CD8-T cells 
that can recognize HLA-A2 presented AFP epitopes, we immunized HLA-A2 transgenic AAD mice 
with AFP-lv and AFP peptide. We found that AFP-lv immunization reproducibly induced a modest 
level of AFP158 epitope-specific CD8 responses in AAD mice (Fig.1A). However, we did not detect 
CD8 responses against other 3 previously identified AFP epitopes (AFP137, AFP325, and AFP542) 
(14). The AFP158 peptide immunization even after prime-boost did not induce CD8 responses. But 
AFP158 epitope boost markedly increased the magnitude of AFP158-specific CD8 responses in the 
AFP-lv primed mice (Fig.1A). Critically, the mouse CD8-T cells from immunized mice produced 
IFNγ after co-culture with the AFP+, but not the AFP-, HepG2 tumor cells (Fig.1B), suggesting that 
the AFP vaccine-activated mouse CD8-T cells could specifically recognize AFP+ HepG2 tumor 
cells. In addition, after co-culture with the immunized mouse splenocytes, AFP+ HepG2 tumor cells 
were killed in a dose-dependent manner (Fig.1C and 1D).  Together, the data suggest that 
immunization of AAD mice with lv-prime and peptide-boost elicits high level of AFP158-specific 
CD8-T cells that recognize and kill AFP+ human HepG2 tumor cells.  
 
2. Adoptive transfer of the immunized AAD splenocytes prevents, but also eradicates large 
HepG2 tumors in NSG mice. In this adoptive transfer experiment, we found that splenocytes from 
the AFP immunized (but not naïve) AAD mice completely prevented HepG2 tumor cell challenge 
in NSG mice (Fig.2A and 2B). Strikingly, adoptive transfer of splenocytes from the immunized 
AAD mice was able to eradicate HepG2 xenografts as large as 2cm in diameter (Fig. 2C).  
 
3. Adoptive transfer of the AFP158-specific CD8-T cells eradicates human HepG2 tumors in NSG 
mice. To further define the immune cells with antitumor effect, we isolated CD8-T cells from the 
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AFP immunized AAD mice for adoptive cell therapy (Fig3A). The CD8-T cells from AAD mice 
immunized with influenza virus M1 antigen were used as control. We found that adoptive transfer 
of CD8-T cells from the AFP immunized mice eradicated HepG2 tumors in NSG mice (Fig.3B). In 
contrast, the HepG2 tumors continued growing in the NSG mice received the CD8-T cells from M1 
antigen-immunized mice. Next, we isolated the AFP158-specific CD8-T cells by Tet158 tetramer 
staining and sorting (Fig.3C). After adoptive transfer, whereas the Tet158- CD8-T cells did not 
inhibit HepG2 tumor growth, the Tet158+ CD8-T cells could eradicate HepG2 tumors in NSG mice 
(Fig.3D). Together, the in vitro and in vivo data verify that the HLA-A2 mouse CD8-T cells specific 
for the HLA-A2 presented AFP158 epitope can recognize and kill human HCC tumor cells.  
 
4. T cell hybridomas created from the Tet158+ CD8-T cells bind to Tet158 tetramer. To identify 
paired TCRα and β chains, we created T cell hybridoma clones. Prior to generating T cell 
hybridomas, the TCR Vβ chains of Tet158+ cells were characterized and >90% of the Tet158+ CD8-
T cells could be stained by anti-Vβ8.3 antibody (Supporting Fig.S1). The other 10% of Tet158+ 
CD8-T cells were stained with antibodies against Vβ2, Vβ4, Vβ5.1/5.2, Vβ6, or Vβ11. We then 
created 39 T cell hybridomas that could bind Tet158 tetramer from 2 cell fusion experiments, 
(Fig.4A). Twenty-five of them could be stained by anti-Vβ8.3 antibody (data not shown). Further 
experiment showed that 5 of the anti-Vβ8.3+ T cell hybridomas responded to AFP+ HepG2 tumor 
cells and produce IL-2 (Fig.4B).  
 
5. Three sets of paired TCRα and β chain are identified from 5 T cell hybridomas. In this 
experiment, the paired TCRα and β chains from the 5 hybridomas capable of producing IL-2 after 
co-culture with HepG2 tumor cells were amplified and sequenced. The result was summarized in 
Fig.4C. Out of these 5 hybridoma clones, 3 unique sets of TCR genes were identified. The 
sequences of TCR2 and TCR4 are identical, so are the TCR3 and TCR5. The amino acid sequences 
of TCRα and β chains were compared to the NCBI and IMGT databank. The data show that all 
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three TCRα chains have the same variable region (TRAV7D-2) and that the TCRβ chains also share 
the same variable region (TRBV13-1) (consistent with anti-Vβ8.3 antibody staining). Detail 
analysis reveals that the sequence of TCR1 and TCR2 is very similar. The β chain of TCR1 and 
TCR2 are identical and the α-chain of TCR1 and TCR2 had two amino acid differences in the V-J 
junction. On the other hand, the TCR3 is more divergent from TCR1 and TCR2. Although the β 
chain of TCR3 is only one amino acid difference from TCR1 and TCR2, the J region of α chain is 
encoded by a different gene. The TRAJ12 of TCR3 α chain has 10AA difference from the TRAJ30 
of TCR1 and TCR2 α chains. 
    
6. Expression of the paired TCR α and β chains in human T cells forms functional TCRs that 
bind Tet158 tetramer. In this study, we investigated whether the AFP-specific TCR genes could 
engineer human T cells to create TCR-T that recognize HLA-A2/AFP158 complex. To this end, we 
synthesized the TCR1, TCR2, and TCR3 genes and cloned them into lv (Fig.5A). In the first 
experiment, we transduced Jurkat cells with TCR-lv and found that gene transfer of any of the three 
sets of TCR genes could effectively enable Jurkat cells to bind Tet158 tetramer, indicating the TCR 
gene expression in Jurkat cells can form functional TCR (Fig.5B). The MFI of Tet158 staining on 
the TCR3-transduced Jurkat cells was higher. Then, we studied whether the TCR genes could 
engineer primary human T cells to redirect them to recognize HLA-A2/AFP158 complex. Primary 
human T cells could be transduced by lv following CD3/CD28 activation. Using GFP as reporter 
protein, at MOI of 10, approximately 60% of human T cells could be transduced by GFP-lv 
(Supporting Fig.S2). Transduction of primary human T cells with TCR genes enabled 
approximately 20-30% of them to bind Tet158 tetramer (Fig.5C). Although the T cells from different 
donors may be transduced with different efficacy, there was no significant transduction difference 
among the 3 sets of TCR genes. Again, the MFI of Tet158 tetramer was consistently higher on the 
TCR3-transduced CD8 and CD4 T cells than TCR1- and TCR2-transduced cells, indicating that 
TCR3 may have higher affinity for the HLA-A2/AFP158. Both CD8 and CD4 TCR-T cells could 
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bind Tet158 Tetramer. However, the MFI of Tet158 staining on CD8-TCR-T was always higher than 
that on CD4 TCR-T cells (Fig.5D), suggesting that CD8 may enhance the binding of TCR to HLA-
A2/AFP158 complex. In addition, the transduced human T cells were stained with anti-TCR Vβ 8.3 
or Tet158 tetramer separately. The percent of Tet158 + cells was nearly identical to the percent of anti-
TCR Vβ8.3+ cells (Supporting Fig S3), suggesting there was no mispairing with endogenous human 
TCRs.   
 
7. TCR-T can be specifically activated by AFP158 peptide and by AFP+ HepG2 tumor cells. To 
study whether the human TCR-T cells could be specifically activated by HLA-A2 presented AFP158 
peptide, we first measured the cytokine production of human TCR-T after stimulation with HLA-A2 
splenocytes pulsed with AFP158 peptides. The data showed that human TCR-T cells could be 
specifically stimulated to produce IFNγ by HLA-A2 cells pulsed with AFP158 peptide. In contrast, 
no IFNγ was detected in the human TCR-T culture after stimulation with influenza virus M1 peptide. 
The mock transduced T cells did not respond to AFP158 peptide stimulation (Supporting Fig S4A). 
The IFNγ production was mainly from CD8-T cells (Fig.S4B), while the IL2 was also produced by 
CD4-T cells (Fig.S4C). Next, we found that human TCR-T cells could recognize HLA-A2+ AFP+ 
HepG2 tumor cells and produce IFNγ (Fig.6A). In contrast, HLA-A2+ AFP- or HLA-A2- AFP+ 
human tumor cells could not activate TCR-T cells. Again, the IFNγ production was mainly 
produced in CD8-TCR-T cells (Fig.6B). But both CD4 (Fig. 6C) and CD8 (Fig.6B) TCR-T cells 
were able to produce IL-2. There was no significant difference among the three TCRs. Furthermore, 
the induction of TCR-T proliferation by HepG2 cells was studied. We found that, after co-culture 
with the HepG2 cells, the human TCR-T cells, especially the CD8-T cells, underwent significant 
proliferation (Fig.6D).  
 
8. Human TCR-T cells have strong and specific cytotoxicity against HLA-A2+AFP+ tumor cells. 
We then studied the cytotoxicity of human TCR-T cells. Using LDH assay, we first showed that 
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human TCR-T cells could kill 80% of HepG2 tumor cells in 24 hours at low E/T ratio. In contrast, 
the TCR-T cells did not generate significant cytotoxic effect on the AFP- or HLA-A2- tumor cells 
(Fig.7A). The cytotoxicity against HepG2 cells was dose-dependent (Fig.7B). At E/T ratio of 0.5 
(the Tet158+ cells is ~30%, thus the E/T ratio was only 0.15), there was a >50% of killing after 24 
hours co-culture. By using purified CD8- and CD4-T cells to conduct cytotoxicity assay, we showed 
that HepG2 tumor cell killing activity was mainly from the CD8-T cells (Fig.7C-E). However, the 
CD4 TCR-T also had a lower level of cytotoxicity, resulting in 15% of specific killing of HepG2 
tumor cells at ratio of 1.5/1 (Fig.7E). After 24 hours of co-culture, the CD8 TCR-T cells encircled 
the HepG2 tumor cells to form clusters (Fig. 7D). On the other hand, the CD4 TCR-T and mock-
transduced T cells did not form obvious clusters. In addition, the PI staining revealed that the cluster 
contained a lot of dead cells (Fig.7F). The PI staining showed that, whereas CD8 TCR-T cells may 
have the dominant cytotoxicity, the CD4 TCR-T cells also had a lower activity of killing hepG2 
tumor cells, in agreement with LDH assay. The mock-transduced human T cells did not induce cell 
death of HepG2 tumor cells in all assays.  
 
9. Adoptive transfer of human TCR-T cells generates antitumor effect against HepG2 tumors in 
NSG mice. In this experiment, we studied the in vivo antitumor effect of human TCR-T. Primary 
human T cells were transduced with lv and approximately 40% of total T cells (25% of CD8 T cells 
and 54% of CD4 T cells) were Tet158+ TCR-T cells before adoptive transfer (Fig.8A). We found 
that adoptive transfer of human TCR-T cells could inhibit HepG2 tumor outgrowth in NSG mice 
(Fig.8B). One of the TCR-T treated-mice developed tumor, but the tumor was then eradicated by 3 
weeks after adoptive transfer (Fig.8C and 8D). The kinetics of the transferred human T cells showed 
that both mock-T and TCR-T cells survived approximately 3-4 weeks in the absence of human IL-2 
(Fig.8E). But compared to mock-T cells, there was a significant increase of the percentage of 
Tet158+ cells among the TCR-T, especially the CD4 TCR-T cells on day 8 after transfer (Fig.8F), 
suggesting that there might be an antigen-induced TCR-T expansion.    
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Discussion 
 
In this study, utilizing an effective immunization strategy of lv-prime and peptide-boost, we 
obtained a large number of AFP158-specific (Tet158) mouse CD8-T cells that could specifically recognize 
and kill human HepG2 tumor cells in vitro and eradicated large HepG2 tumor xenografts in NSG mice. 
Subsequently, we established T cell hybridomas from the Tet158 CD8-T cells, which allowed us to identify 
three sets of paired TCR α and β chain that could bind the HLA-A2/AFP158. The TCR genes could enable 
human CD8-T cells to specifically recognize and kill HepG2 tumor cells in vitro. Furthermore, adoptive 
transfer of the TCR-T cells could prevent tumor outgrowth and even eradicated HepG2 tumors in NSG 
mice.  
TCR-T cells have been studied in a number of clinical trials (35), which include TCRs specific 
for tumor-associated antigens of p53 (36), CEA (37), MAGE3 (24, 25), GP100 (18), MART1 (38), and 
NY-ESO (39). Most of the TCR genes, including the AFP158-specific TCRs reported recently (22, 23), are 
isolated from T cell clones established by repeated in vitro antigen stimulation, which may significantly 
reduce the TCR diversity. For example, after 4 weeks of in vitro stimulation, only one TCR sequence was 
found in 19 of the GPC3367-specific T cell clones (40). Compared to this conventional approach of 
repeated in vitro antigen stimulation, we established an effective in vivo immunization strategy in the 
HLA-A2 mice using one lv-prime and one peptide-boost. This approach generates a large number of 
AFP158-specific CD8-T cells for us to determine their specific recognition and killing of tumor cells and 
to validate their antitumor function in vivo without repeated stimulation. Furthermore, the creation of T 
cell hybridomas directly from murine CD8-T cell without stimulation should maintain a diverse TCR 
repertoire. Not surprisingly, we were able to identify 3 unique sets of paired TCR α and β chains out of 5 
T cell hybridoma clones. In addition to the 3 TCR genes we have identified, there are additional 34 T cell 
hybridomas that can bind Tet158 tetramer. Their production of low level or no production of IL-2 after 
antigen stimulation may be due to the loss of IL-2 or signaling protein genes involved in IL-2 production 
during cell fusion. However, the positive staining of these hybridomas by Tet158 tetramer indicates the 
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presence of AFP158-specific TCRs, which can still be the resource for finding an optimal TCR of strong 
antitumor activity without on-target and off-target toxicity.  
TCRs specific for human tumor antigens can be derived from human or HLA-A2 transgenic mice. 
Human TCR is inherently low affinity because of negative selection during thymus development, and 
may require affinity enhancement to achieve effective recognition of tumor antigens (41) (and Gerry et al, 
Improved affinity AFP-specific T cell receptor for hepatocellular carcinoma, Journal for ImmunoTherapy 
of Cancer, 2013 1 (Suppl 1):P10). On the other hand, murine TCR from HLA-A2 mice can recognize 
human antigenic epitopes with high affinity. However, high affinity TCRs have a higher chance of cross-
recognizing off-target antigens (42), resulting in toxicity. It was previously showed that the TCR derived 
from conventional HLA-A2 mice had higher affinity than the TCR derived from the HLA-A2/K
b
 mice 
(43). Thus, in our study, we purposely used the HLA-A2 transgenic AAD mice, in which the MHC I is a 
chimeric molecules consisting of the α1-α2 domain of HLA-A2 and α3 domain of mouse H-2
d
. The AAD 
MHC I molecule will make the mice more responsive to antigen immunization because mouse CD8 
molecule can bind the mouse α3 domain of MHC to provide the help for engagement of T cells with 
antigen presenting cells. At the same time, the provision of CD8 help should increase the chance of 
generating CD8-T cells with optimal TCR affinity (not very high affinity). In addition, the use of murine 
TCRs can minimize mispairing with endogenous human TCRs (44), reducing the chance of creating off-
target toxicity and increase the on-target effect. In our study, we found that the percent of TCR Vβ chain+ 
cells is very close to the percent of Tetramer+ cells, suggesting that, indeed, there is no TCR mispairing in 
the transduced human T cells. However, murine TCR was found to be immunogenic in a portion of 
patients (36), thus humanization may be needed for repeated use of TCR-T in patients.  
The 3 sets of AFP158-specific murine TCRs identified in this study are also able to render CD4-T 
cells the capability of binding Tet158 tetramer. The production of IL-2 by CD4 TCR-T cells in response to 
HepG2 tumor cells stimulation may provide the cytokine for maintaining T cell proliferation in vivo. In 
addition, the CD4 TCR-T cells demonstrate a low cytotoxicity against HepG2 tumor cells. Thus, although 
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the CD8-TCR-T may be the major player for killing AFP+ tumor cells, the CD4 TCR-T can provide the 
help for T cell proliferation, which can be critical for generating antitumor effect in vivo.   
Adoptive transfer of TCR-T cells has generated remarkable antitumor effect in multiple myeloma 
(45), and in synovial cell sarcomas and melanoma (46), suggesting they have a great potential to control 
solid tumor growth. However, in light of the severe toxicity recently observed after adoptive transfer of 
melanoma antigen MAGE-A3 specific TCR-T cells (24, 25, 47), the on-target and off-target toxicity of 
the AFP-specific TCR-T cells should be extensively examined in preclinical models (Gerry et al, J Clin 
Oncol 34, 2016 (Suppl: abstract 3051) before conducting clinical trials to test their antitumor effect. The 
diverse TCR repertoire in the pool of our T cell hybridomas should give us a higher chance of finding the 
right TCR genes with strong antitumor effect but without causing severe on-target and off-target toxicity. 
These AFP-specific TCR genes identified in this study, if proved to be safe, should have a great potential 
of being used to modify patient’s autologous T cells for adoptive cell therapy of HCC.  
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Fig.1 Immunization with lv-prime and peptide-boost elicits high level of AFP158-specific CD8-T cells that 
recognize and kill human HepG2 tumor cells. (A) HLA-A2 transgenic AAD mice were primed with AFP-lv and 
boosted with AFP158 peptide. The CD8 responses were analyzed 12days after prime and 5days after boost. 
Peripheral blood cells from the indicated mice were analyzed for CD8 and IFNγ by gating on the Thy1.2+ T 
cells after ex vivo stimulation with AFP158 peptide. Representative dot plots and a summary of 5 mice were 
shown. (B) Splenocytes of the immunized mice were co-cultured with AFP- or AFP+ HepG2 cells for 4hrs and 
analyzed for IFNγ. Stimulation with AFP158 peptide was used as positive control. Representative plots and a 
summary of 5 mice were shown. T-test was used for statistical analysis. (C) HepG2 cells were co-cultured 
with the splenocytes of immunized mice overnight and pictures were taken. (D) MTT assay was performed 
to determine the remaining live HepG2 cells after splenocytes were rinsed away. The MTT data of HepG2 
tumor cells co-cultured with different ratios of splenocytes was compared to MTT data of HepG2 tumor cells 
alone to calculate % of live cells. Shown is the dose-dependent killing of HepG2 cells by splenocytes of the 
immunized mice. ANOVA was used for statistical analysis. The experiment was done three times with similar 
data. Lv+Pep: lv-primed and peptide-boost; Pep+Pep: peptide-prime and peptide-boost.  
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Fig. 2 Adoptive transfer of the immunized AAD mouse splenocytes prevents tumor challenge and eradicates 
large HepG2 tumor xenografts. (A) Approximately 11% of the prime-boosted AAD mouse splenocytes 
produced IFNγ in response to AFP158 peptide. (B) In the preventive model, 15 millions of total splenocytes 
of the naïve or immunized mice were injected into NSG mice, which were followed by HepG2 tumor cell 
challenge 2 days later. Tumor size was measured and record. (C) In the therapeutic model, NSG mice were 
injected with 15 million of total splenocytes of the immunized mice when HepG2 tumor size reaches 2cm in 
diameter. Shown is the tumor volume curve. The experiment was done twice with similar data.  
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Fig. 3 Adoptive transfer of AFP158-specific CD8-T cells eradicates HepG2 tumors in NSG mice. (A) The CD8-
T cells from AFP-immunized mice were isolated by magnetic beads.  The CD8-T cells from mice immunized 
with influenza virus M1 antigen peptide were used as control. The purity of CD8-T cells and the percent of 
IFNγ-producing cells were shown. (B) NSG mice bearing HepG2 tumors were injected with 5 million of CD8-T 
cells from AFP- or M1-immunized mice (~0.5 million of AFP-specific and 1.5 million of M1-specific CD8-T 
cells, respectively). Tumor growth curve was shown. (C) The magnetic beads purified CD8-T cells from AFP 
immunized mice were further separated into Tet158+ and Tet158- cells by Tet158 tetramer staining and cell 
sorting. The purity before and after sorting was presented. (D) NSG mice bearing HepG2 tumors were 
injected with 0.5 million of Tet158+ or Tet158- CD8-T cells. The tumor growth curve and tumor pictures at 
end of experiment were presented.  
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Fig. 4 Paired TCRα and β chains are identified from the T cell hybridomas that bind to Tet158 tetramer. (A) 
The T cell hybridomas were established from sorted Tet158 cells. Representative tetramer staining of 5 
hybridomas was shown. BW-Lyt2.4 fusion partner cells were negative control. (B) T cell hybridomas 
produced IL-2 in response to AFP+, but not AFP-, HepG2 tumor cells. (C) Paired TCRα and β chains were 
identified from 5 hybridomas and their TCR genes were summarized. TCR4 and TCR2 are identical, so are 
TCR5 and TCR3. The protein sequences of TCR-1 and TCR-2 α chains have 2AA difference in the V-J 
junction, whereas the TCR-3 α chain has 10AA difference from TCR-1 and TCR-2 in the J region. The protein 
sequences of TCRβ chain are identical except that TCR-3 has one AA difference from TCR-1 and TCR-2 in the 
D-J Junction.  
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Fig. 5 Expression of the paired TCR α and β chains forms TCRs that bind Tet158 tetramer. (A) The sketch of 
a recombinant lv expressing TCR gene was shown. The paired TCR α and β chain genes were expressed as a 
single molecule under the control of EF1α promoter. A P2A sequence was inserted in between to allow 
generation of equal number of TCR α and β chains. (B) Tet158 tetramer staining of the human T cell line 
Jurkat cells after transduction with three different TCR-lv. Histogram and MFI were presented. (C and D) 
Primary human T cells from 3 different donors were transduced with TCR-lvs and the transduction efficiency 
was examined 7-10 days after lv transduction. Both the percent (C) and MFI (D) of Tet158+ CD8 and CD4 T 
cells were presented. Mock transduced T cells had undergone same CD3/CD28 treatment without lv 
transduction.  
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Fig. 6 Human TCR-T can be specifically activated by HLA-A2 presented AFP158 peptide and by AFP+ HepG2 
tumor cells. (A-C) The human TCR-T cells were co-cultured 6hours with HLA-A2+AFP+ HepG2 cells, HLA-
A2+AFP- HepG2 cells, or HLA-A2-AFP+ tumor cells. (A) The level of IFNγ level in the medium was measured 
by ELISA assay. Intracellular staining of IFNγ and IL-2 by CD8 (B) and CD4 (C) TCR-T cells after stimulation 
with HLA-A2+AFP+ HepG2 cells was also shown. Only the CD8 or CD4 T cells were gated and shown in the 
representative plots. (D) The induction of CD8 and CD4 TCR-T cell proliferation was examined after 2day co-
culture with AFP+ HepG2 tumor cells. The experiment was repeated twice with similar data.  
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Fig. 7 CD8 TCR-T cells have strong and specific cytotoxicity against HLA-A2+ AFP+ HepG2 cells. (A) Donor T 
cells transduced by different TCR genes were co-cultured overnight in triplicate with indicated tumor cells at 
E/T ratio of 5. The killing efficacy of HepG2 tumor cells by human TCR-T (both CD8 and CD4) cells was 
measured by LDH assay. (B) Dose dependent killing of AFP+ HepG2 tumor cells was shown by TCR-T cells. 
(C) Donor CD8 and CD4 TCR-T cells were separated by magnetic beads after TCR gene transduction. (D) Co-
culture of the mock-transduced, CD4, or CD8 TCR-T cells with HepG2 tumor cells. Pictures were taken at 
2hours and 24hours after co-culture. (E) LDH assay was conducted at 24hours after co-culture to measure 
the killing effect. Statistical analysis was done with t-test. (F) PI staining of the TCR-T and HepG2 tumor cell 
co-cultures after 24hours to reveal dead cells. The experiment was repeated trice with similar data.  
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Fig.8 Adoptive transfer of TCR-T prevents and regress HepG2 tumors in NSG mice. (A) NSG mice bearing 4 
day HepG2 tumors were adoptively transferred with 20 million of human TCR-T. The % of Tet158+ cells in 
the human TCR-T cells was shown. Tumor outgrowth and TCR-T in the mice were monitored. (B and C) The 
outgrowth and the volume of each tumor were presented. (D) Pictures of HepG2 tumors at day 31 after 
inoculation were taken. (E) Representative dot plots showed the % of human CD45+ cells among mouse 
blood cells. The kinetics of hCD45+ cells in NSG mice was summarized from 4 mice. (F) The % of Tet158+ 
out of the transferred human T cells in the NSG mice was presented. The kinetics of Tet158+ cells among 
total transferred total human T cells, CD8, and CD4 T cells were summarized from 4 mice. The experiment 
was repeated twice with similar data.  
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